| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 1891 | 2020 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1648 | 2018 |
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... J Clin oncol 33 (9), 983-991, 2015 | 1097 | 2015 |
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ... The lancet oncology 15 (7), 747-756, 2014 | 1087 | 2014 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 891 | 2018 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 591 | 2020 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 580 | 2022 |
| Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. TJ Vogl, S Kümmel, R Hammerstingl, M Schellenbeck, G Schumacher, ... Radiology 200 (1), 59-67, 1996 | 539 | 1996 |
| A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results … S Loibl, M Untch, N Burchardi, J Huober, BV Sinn, JU Blohmer, ... Annals of Oncology 30 (8), 1279-1288, 2019 | 534 | 2019 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association … E De Azambuja, AP Holmes, M Piccart-Gebhart, E Holmes, S Di Cosimo, ... The lancet oncology 15 (10), 1137-1146, 2014 | 520 | 2014 |
| Response-guided neoadjuvant chemotherapy for breast cancer G von Minckwitz, JU Blohmer, SD Costa, C Denkert, H Eidtmann, ... Journal of Clinical Oncology 31 (29), 3623-3630, 2013 | 421 | 2013 |
| Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial E Hahnen, B Lederer, J Hauke, S Loibl, S Kröber, A Schneeweiss, ... JAMA oncology 3 (10), 1378-1385, 2017 | 405 | 2017 |
| Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial M Untch, C Jackisch, A Schneeweiss, B Conrad, B Aktas, C Denkert, ... The lancet oncology 17 (3), 345-356, 2016 | 402 | 2016 |
| Real‐time elastography—an advanced method of ultrasound: first results in 108 patients with breast lesions A Thomas, T Fischer, H Frey, R Ohlinger, S Grunwald, JU Blohmer, ... Ultrasound in Obstetrics and Gynecology: The Official Journal of the …, 2006 | 389 | 2006 |
| Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial G von Minckwitz, S Kümmel, P Vogel, C Hanusch, H Eidtmann, J Hilfrich, ... Journal of the National Cancer Institute 100 (8), 542-551, 2008 | 355 | 2008 |
| Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials G von Minckwitz, M Untch, E Nüesch, S Loibl, M Kaufmann, S Kümmel, ... Breast cancer research and treatment 125, 145-156, 2011 | 339 | 2011 |
| West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local … O Gluz, UA Nitz, M Christgen, RE Kates, S Shak, M Clemens, S Kraemer, ... Journal of Clinical Oncology, 2016 | 321 | 2016 |
| Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 … P Schmid, R Salgado, YH Park, E Muñoz-Couselo, SB Kim, J Sohn, SA Im, ... Annals of Oncology 31 (5), 569-581, 2020 | 319 | 2020 |
| Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study G von Minckwitz, S Kümmel, P Vogel, C Hanusch, H Eidtmann, J Hilfrich, ... Journal of the National Cancer Institute 100 (8), 552-562, 2008 | 314 | 2008 |
| Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis H Haller, MM Winkler, P Klose, G Dobos, S Kuemmel, H Cramer Acta oncologica 56 (12), 1665-1676, 2017 | 274 | 2017 |
sibylle loiblProfessor for medicineVerified email at gbg.de
